Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Tamoxifen and its analogues are powerful tools in the fight against breast cancer and may soon find applications fighting other diseases such as atherosclerosis and osteoporosis.
The discovery of hyperhomocysteinemia as a major factor in the pathogenesis of arteriosclerosis offers new strategies and opportunities for prevention and treatment.
Loss of response to TGF-βs may be an important step in the development and progression of cancer. Recent studies show that receptors and proteins involved in TGF-β signaling may act as tumor suppressors.
A mathematical model is used to suggest why strain diversity of pathogenic microorganisms persists in the face of constant opportunities for recombination (pages 437–442).
